Kyowa Hakko Kirin and Kyowa Kirin International Announce Burosumab Data Presentations at ASBMR 2017 Annual Meeting

By Drugs, JPN

Kyowa Hakko Kirin and Kyowa Kirin International Announce Burosumab Data Presentations at ASBMR 2017 Annual Meeting

Tokyo, Japan and London, UK — August 24, 2017 — Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) and Kyowa Kirin International PLC (Kyowa Kirin International), a wholly owned subsidiary of Kyowa Hakko Kirin, today announced upcoming presentations of data highlighting burosumab for the treatment of X-linked hypophosphatemia (XLH) and tumor- induced osteomalacia (TIO) at the American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting taking place September 8-11 in Denver, Colorado.

http://www.kyowa-kirin.co.jp/news_releases/2017/pdf/20170824_02.pdf

More from tokioX :

  1. 💊FDA & PHARMA TODAY
  2. 💊Kyowa Hakko Kirin Announces the Intent to File Istradefylline (KW-6002) for Parkinson’s Disease with the US FDA
  3. 💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application 20171010
  4. 💊Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)
  5. 🚀DLR-JAXA Joint Statement concerning the bilateral cooperation  2017/09/20
  6. Notice of business / capital alliance with Pioneer, HERE International B.V. (HERE Technologies) and issue of new shares through third-party allocation (PDF 270 KB)
  7. PDF]US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the treatment of Mycosis Fungoides and Sézary Syndrome  Kyowa Hakko Kirin News Releases